Among nine TGFβ-targeting programs with presentations at ASCO21, nearly all have a dual targeting strategy, and five are testing the hypothesis that targeting the immunosuppressive cytokine

BioCentury | Aug 26, 2020

Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Connect raises $115M C round, eyes pivotal trialsRA Capital’s Derek DiRocco will join the board of Suzhou Connect Biopharmaceuticals Ltd. after the firm led the Chinese biotech’s

BioCentury | Feb 21, 2018

Distillery Therapeutics

Science spotlight: RNA-based enzymes for DNA editing; plus XIST-driven autoimmunity and more

Grafting iPSC-derived tenocytes to restore motor function after Achilles tendon rupture

Two rapid CRISPR-based COVID-19 tests for at-home and point-of-care settings

Fusion proteins lead in TGFβ blockade at ASCO21: Data Byte

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

Cancer

Drug platforms

Technology: Drug platforms

Isarna Therapeutics, Santaris, GlaxoSmithKline, Roche deal

Scleroderma models: skin in the game